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ABSTRACT
Postherpetic neuralgia (PHN) is a common, very
painful, and often long-lasting complication of
herpes zoster which is frequently
underdiagnosed and undertreated. It mainly
affects the elderly, many of whom are already
treated for comorbidities with a variety of
systemic medications and are thus at high risk
of drug–drug interactions. An efficacious and
safe treatment with a low interaction potential
is therefore of high importance. This review
focuses on the safety and tolerability of the 5%
lidocaine medicated plaster, a topical analgesic
indicated for the treatment of PHN. The
available literature (up to June 2014) was
searched for publications containing safety
data regarding the use of the 5% lidocaine
medicated plaster in PHN treatment;
unpublished clinical safety data were also
included in this review. The 5% lidocaine
medicated plaster demonstrated good short-
and long-term tolerability with low systemic
uptake (3 ± 2%) and minimal risk for systemic
adverse drug reactions (ADRs). ADRs related to
topical lidocaine treatment were mainly
application site reactions of mild to moderate
intensity. The treatment discontinuation rate
was generally below 5% of patients. In one trial,
the 5% lidocaine medicated plaster was better
tolerated than systemic treatment with
pregabalin. The 5% lidocaine medicated
plaster provides a safe alternative to systemic
medications for PHN treatment, including long-
term pain treatment.
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INTRODUCTION
Postherpetic neuralgia (PHN) is the most
common complication of herpes zoster [1].
Transition from acute herpes zoster to PHN
occurs when pain persists 3 months or more;
definitions, however, vary from as short as
1 month to as long as 6 months after lesion
crusting. PHN pain may be spontaneous or
stimulus evoked, constant or intermittent, and
with qualities such as burning, throbbing,
aching, shooting, or stabbing [1, 2]. Allodynia
is common and often considered the most
distressing and debilitating component of the
disease [3]. PHN has a substantial detrimental
effect on all aspects of patients’ quality of life
[4, 5]. The condition remains underdiagnosed
and often undertreated, particularly in primary
care [6]. Incidence of PHN markedly increases
with age [7–10].
The topical analgesic 5% lidocaine
medicated plaster (Versatis, Gru¨nenthal
GmbH, Aachen, Germany) is recommended
for localized peripheral neuropathic pain [11–
13] and first line especially in frail and elderly
patients when there are concerns regarding side
effects or safety of other treatments [13]. It is
registered in the USA (as Lidoderm, Endo
Pharmaceuticals, Chadds Ford, PA, USA) and
in many European, Latin American, and Middle
Eastern countries. The plaster is approved in
approximately 50 countries worldwide for the
symptomatic relief of neuropathic pain
associated with previous herpes zoster
infection and additionally in nine of these
countries for localized neuropathic pain
treatment. Since the first marketing
authorization in 1999 until June 2014, it is
estimated that the lidocaine plaster has been
prescribed to approximately 20 million patients
[14].
The analgesic efficacy of the 5% lidocaine
medicated plaster in PHN treatment was
demonstrated in several randomized clinical
studies [15–19]. The 5% lidocaine medicated
plaster is the only PHN treatment with available
safety and efficacy clinical data on long-term
treatment up to 4 years [20, 21]. Moreover,
effectiveness, tolerability, and patient
satisfaction were documented for up to 7 years
of daily plaster use [22]. A recent publication
comprehensively reviews the efficacy of the 5%
lidocaine medicated plaster in pain
management [23]. No analysis of pooled data
on adverse drug reactions (ADRs),
discontinuation data, comparison with
systemic medication, and safety in certain
higher-risk patient populations has been
published so far. This review focuses on this
clinical safety and tolerability profile of the 5%
lidocaine medicated plaster.
METHODS
A PubMed literature search was conducted for
the time period from 1960 to last update on
June 26, 2014 to identify studies reporting the
occurrence of adverse events (AEs)/ADRs and
other safety issues pertaining to the use of the
5% lidocaine medicated plaster in PHN
treatment. Using the keyword combinations
‘‘lidocaine (lignocaine) and pain and
postherpetic neuralgia and topical, not gel, not
lotion, not cream, not spray’’, ‘‘lidocaine
(lignocaine) and pain and postherpetic
neuralgia and plaster’’, and ‘‘lidocaine
(lignocaine) and pain and postherpetic
neuralgia and patch’’ the search retrieved 160
publications (including duplicates). Screening
of the abstracts identified 18 original
publications reporting on safety. However, in
eleven of these publications, the study
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populations also included patients with pain
diagnoses other than PHN, and safety was not
documented separately for different diagnoses.
To stay within the PHN indication, these
publications outside of the labeled indication
were excluded. As it was intended to describe
the tolerability and safety of the 5% lidocaine
medicated plaster, it was decided to focus on
the occurrence of ADRs and to exclude
publications only reporting AEs. Overall, 6
publications remained [16, 18–21, 24].
Additionally, articles regarding
pharmacological aspects, previous
pharmacokinetic and safety reviews, PHN/5%
lidocaine medicated plaster reviews, case reports
relating to safety issues, the Summary of
Product Characteristics of the lidocaine
medicated plaster [25], and unpublished
clinical safety data from Gru¨nenthal GmbH
were perused for this review.
This review is based on previously conducted
studies and does not involve any new studies of




The plaster consists of a 10 cm 9 14 cm
hydrogel adhesive containing 700 mg of
lidocaine (5% w/w) [25]. A daily application of
up to three plasters (depending on the size of
the painful skin area) to undamaged skin for a
maximum of 12 h with plaster-free intervals of
at least 12 h is recommended. The 5% lidocaine
medicated plaster is placed directly on the
affected area of pain [26].
The hydrogel plaster itself provides an
immediate cooling and soothing perception,
while giving physical protection to the
hypersensitive area of the skin [15, 17]. The
active compound lidocaine is thought to act as
a local analgesic by selective but only partial
inhibition of voltage-gated sodium channels of
damaged or dysfunctional unmyelinated C
fibers and small myelinated Ad fibers [27]. This
pharmacological action is thought to stabilize
the neuronal membrane potential on Ad and C
fibers resulting in a reduction of ectopic
discharges [17, 27–29]. Besides reductions in
pain intensity, the plaster was also shown to
reduce the painful surface area [30]. A positive
effect on allodynia and hyperalgesia was also
observed [31, 32]. The 5% lidocaine medicated
plaster does not cause local anesthesia [32].
Pharmacokinetic Properties
Following plaster application lidocaine is
continuously released at the application site;
only approximately 3 ± 2% of the applied
lidocaine enters systemic circulation [33].
Steady-state plasma concentrations are reached
within 4 days with no tendency for lidocaine
accumulation [25]. Pharmacokinetic studies
and a population kinetics analysis of clinical
efficacy studies observed that mean maximum
lidocaine plasma concentrations were below
0.3 lg/ml using up to four plasters in healthy
volunteers and up to three plasters in patients
with acute herpes zoster or PHN (Fig. 1)
including extended dosing regimens (four
plasters simultaneously, application for 18 h,
continuous 72 h application with plaster
changes every 24 h [28, 34]). When more than
three plasters were applied and an extended
application time was used, increases in area
under the curve and maximum serum
concentration relative to the investigations
using three plasters were documented [28, 34].
However, the observed absorption remained
low, that is, well below the minimum effective
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plasma concentrations during therapy of
cardiac arrhythmias and well below the toxic
range for lidocaine (Fig. 1). Lidocaine plasma
concentrations even remained below 0.5 lg/ml
after 4 months of treatment with ten 5%
lidocaine medicated plasters daily to ease
neuropathic pain in one cancer patient [37].
Although the absorption of lidocaine from
the skin is generally low, the plaster must be
used with caution in patients receiving Class I
antiarrhythmic drugs (e.g., tocainide,
mexiletine) and other local anesthetics,
because the risk of additive systemic effects
cannot be excluded [25]. No drug interaction
studies have been carried out; however, as
systemic absorption is only approximately 3%,
clinically relevant pharmacokinetic interactions
with other medications are unlikely. In
addition, no clinically relevant interactions
have been observed in clinical studies with the
5% lidocaine medicated plaster [25].
Absorbed lidocaine is rapidly and extensively
metabolized in the liver, mainly by N-
dealkylation to monoethylglycinexylidide and
glycinexylidide, which are less active than the
parent compound and present only in low
concentrations [25]. Lidocaine and its
metabolites are primarily eliminated by the
kidneys; less than 10% is excreted unchanged
[25]. The elimination half-life of lidocaine after
plaster application in healthy volunteers is 7.6 h
[25].
ADVERSE DRUG REACTIONS
In the initial trials, AEs were collected using a
pre-specified special symptom checklist to
inquire about untoward local anesthetic or
dermatological effects and systemic adverse
reactions typical for local anesthetics, whereas
in the larger phase 3 trials with the majority of
patients AEs were collected following the
spontaneous reporting concept during
scheduled visits. AEs were encoded according
to the Medical Dictionary for Regulatory
Activities (MedDRA) preferred term with
respective system organ classes, and
frequencies were analyzed descriptively.
For all AEs (i.e., serious and non-serious), the
causal relation to the investigational medicinal
product (IMP) [38] was evaluated by the
investigator, whereas for serious AEs (SAEs) an
additional causality assessment was performed
Fig. 1 Comparison of lidocaine plasma/serum concentrations
after topical application of the 5% lidocaine medicated
plaster (open/white bars) in healthy volunteers and patients
with AHZ or PHN to plasma concentrations associated
with the therapeutic systemic administration (grey bar) and
toxic range for cardiac arrhythmias (black bar). Trials with
various 5% lidocaine medicated plaster treatment regimes
and populations: a 4 plasters administered every 12 h
(twice daily) or 24 h for 3 consecutive days to healthy
volunteers [28]; b 4 plasters administered for 18 h/day for
3 consecutive days to healthy volunteers [34]; c 3 plasters
administered for 12 h/day for 3 consecutive days to
healthy volunteers (Gru¨nenthal, data on ﬁle); c 3 plasters
administered for 12 h for 1 day to patients with AHZ and
to patients with PHN (Gru¨nenthal, data on ﬁle); d 3
plasters administered for 12 h/day for 5 consecutive days
to healthy volunteers (Gru¨nenthal, data on ﬁle); e 3
plasters administered for up to 12 h/day for 1 year to
patients with PHN (mean maximum serum concentration
value; Gru¨nenthal, data on ﬁle). AHZ acute herpes zoster,
PHN postherpetic neuralgia
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by the sponsor. An AE was considered as an
ADR, if either the investigator or the sponsor or
both considered the AE to be at least possibly
related to the administration of the IMP.
In the first double-blind, placebo-controlled,
multiple-dose trial, a list of pre-specified
symptoms were each rated on an intensity
scale before start and at end of treatment [39,
40]. The 5% lidocaine medicated plaster
treatment did not cause any score increases
compared to placebo.
Pooled Analysis
In 2007, four clinical efficacy and safety trials
were pooled to assess the safety profile of the 5%
lidocaine medicated plaster. This analysis has so
far not been published. Overall, 502 patients
(56.4% female) with a mean age of
73.1 ± 8.3 years who had applied at least one
5% lidocaine medicated plaster were included.
The majority of patients (82.5%) were over
65 years of age. Mean PHN duration was
3.0 ± 4.2 years. As described above, the first
double-blind, placebo-controlled, multiple-
dose trial [39, 40] differed from the remaining
three studies [16, 18, 20]. To avoid a bias
regarding the spectrum of reported AE terms
this trial was excluded from the analysis.
Summary information about the included
studies is listed in Table 1.
Overall, 394 patients were included in this
analysis of whom 78 (19.8%) experienced 131
ADRs. None of the ADRs were serious according
to the sponsor’s criteria. The most commonly
affected system organ classes were ‘‘general
disorders and administration site conditions’’
(47 patients/11.9%), followed by skin and
subcutaneous tissue disorders (23/5.8%),
nervous system disorders (9/2.3%), and
gastrointestinal disorders (3/0.8%). In the
majority of patients with ADRs (65/78; 83%),
ADRs were related to the skin with application
site erythema and application site pruritus most
frequently reported (Table 2).
Comparison to Systemic Medication
The safety profile of the topical 5% lidocaine
medicated plaster was directly compared to the
systemic pain medication pregabalin in one
open-label randomized non-inferiority study
[17]. The PHN safety subset included 50
patients under 5% lidocaine medicated plaster
treatment and 48 patients receiving pregabalin
[19]. Mean age of the study population was
64.9 ± 11.8 years with a PHN duration of
3.0 ± 4.8 years. Fifty-five percent of the patients
were male. These data were comparable between
the groups. The 5% lidocaine medicated plaster
was significantly better tolerated than pregabalin
during the 4-week comparative phase
(P\0.0001, exploratory). Five ADRs occurred in
five (10%) patients treated with 5% lidocaine
medicated plaster and included three mild or
moderate application site reactions (erythema,
paresthesia, and rash), a furuncle, and a mental
disorder due to a general medical condition. The
latter was an SAE, which was assessed to be
possibly related to treatment by the investigator.
The outcome was documented as resolved for 3
ADRs (60%) and resolving for 2 ADRs (40%). In
contrast, 82 ADRs in 25 patients were reported
for the pregabalin group (Fig. 2), mainly
consisting of dizziness (9 patients/18.8%),
fatigue (8/16.7%), somnolence (3/6.3%), and
headache (3/6.3%). Twenty-two of these ADRs
were of severe intensity. Nine of the 82 ADRs
(11%) were reported as not resolved, resolved
with sequelae, or had an unknown outcome.
Two patients in the 5% lidocaine medicated
plaster group (4%) and 13 receiving pregabalin
(27.1%) discontinued treatment prematurely
(Fig. 2). These ADRs were application site rash
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and mental disorder due to a general medical
condition for the lidocaine plaster; main reasons
for pregabalin discontinuation were fatigue (3
patients), dizziness (2), and somnolence (2).
Twenty-five patients receiving the 5%
lidocaine medicated plaster and 14 pregabalin-
treated patients had experienced sufficient pain
relief during the 4-week comparative phase to
continue treatment with their allocated
medication in monotherapy for another
8 weeks. During this time, two patients in the
5% lidocaine medicated plaster group reported
application site rash, application site erythema,
and erythema and three patients under
pregabalin reported dizziness and headache.
All ADRs related to 5% lidocaine medicated
plaster resolved; one pregabalin-related ADR of
dizziness was not resolved. One patient in each
treatment group withdrew prematurely due to
an ADR (erythema for the 5% lidocaine
medicated plaster, headache for pregabalin).
Long-term Treatment
In 2009, a prospective, open-label, multicenter,
phase III, large-scale 12-month study
investigated efficacy, safety, and patient
satisfaction with the 5% lidocaine medicated
plaster in PHN treatment [20]. After completion
of the main trial period, a total of 102 patients
continued treatment with the plaster, and
safety data are available for the complete
treatment duration of more than 5 years [21].
The study population was predominantly
elderly (mean age 71.3 ± 9.2 years) with a
higher proportion of females (63.7%) and had
been suffering from PHN for 2.6 ± 3.0 years.
Patients applied a mean of
1.8 ± 0.6 plasters/day for up to 12 h daily.
Over the more than 5 years of treatment, the
ADR incidence was low: 19 patients (18.6%) had
30 AEs that were considered by the investigators
as probably/likely related (n = 13) or possibly
related (n = 17) to 5% lidocaine medicated
plaster treatment. None of these ADRs were
serious. They were mainly application site
Table 2 Integrated safety analysis: adverse drug reactions
related to the 5% lidocaine medicated plaster involving the
skin
Study population 394 (100%)
Patients with adverse drug reactions related
to the skin
65 (16.5%)
Application site erythema 15 (3.8%)
Application site pruritus 11 (2.8%)
Erythema 10 (2.5%)
Application site pain 8 (2.0%)
Application site irritation 7 (1.8%)
Rash 7 (1.8%)
Application site dermatitis 6 (1.5%)
Application site hypersensitivity 5 (1.3%)
Pruritus 5 (1.3%)
Pain of skin 2 (0.5%)
Application site anesthesia 1 (0.3%)
Application site excoriation 1 (0.3%)
Application site hyperesthesia 1 (0.3%)
Application site inﬂammation 1 (0.3%)
Application site edema 1 (0.3%)
Application site pustules 1 (0.3%)
Application site vesicles 1 (0.3%)
Dermatitis 1 (0.3%)
Dermatitis allergic 1 (0.3%)
Skin discoloration 1 (0.3%)
Skin irritation 1 (0.3%)
Skin lesion 1 (0.3%)
Urticaria 1 (0.3%)
Urticaria localized 1 (0.3%)
Data are number of patients (%)
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reactions (14 patients) including
hypersensitivity (4), erythema (3), irritation
(3), pruritus (3), rash (2), and skin reaction (1)
and resolved without further treatment after
removal of the plaster. Investigators also
classified dysgeusia, myalgia, hypoglycemia,
unilateral deafness, tinnitus, tachycardia,
paresthesia, pruritus, rash, skin irritation,
and urticaria (all single cases) as possible
ADRs. Only three patients (2.9%)
discontinued the study prematurely, all due
to drug-related application site
hypersensitivities. Table 3 compares the
safety data of this long-term trial to other
pivotal open-label PHN trials.
Telephone follow-up interviews and a
mailed survey also reported a good safety
profile for the 5% lidocaine medicated plaster
in individual patients treated for PHN for up
to 5 years [41] and 7 years [22], respectively.
Overall, the 5% lidocaine medicated
plaster was well tolerated during long-term
PHN treatment.
Further Open-Label Data
A prospective, multicenter, open-label,



































































































































































































































































































































































































































































































































Fig. 2 Adverse drug reactions during 4-week treatment
with the topical 5% lidocaine medicated plaster or systemic
pregabalin [19]. *P\0.0001 (exploratory) compared to
pregabalin
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the 5% lidocaine medicated plaster regarding
pain relief and improvement of quality of life in
332 patients with PHN (mean age 71 years, 60%
female) observed localized rash as the most
common ADR (12% of patients) [24]. ADRs
related to the following system organ classes
were reported: skin/subcutaneous disorders (40
patients/12%), nervous disorders (19/6%),
general disorders and administration site
conditions (16/5%), gastrointestinal disorders
(5/2%), eye disorders (3/1%), immune system
disorders (3/1%), psychiatric disorders (2/\1%),
cardiac disorders, musculoskeletal, connective
tissue and bone disorders, vascular disorders, ear
and labyrinth disorders, and injury and
poisoning (all 1/\1%). No serious systemic
ADRs were reported.
In accordance with the clinical data, post-
marketing experience of the 5% lidocaine
medicated plaster found application site
reactions such as rash, pain, erythema,
pruritus, skin irritation, and vesicles, the most
commonly reported ADRs. Open wound,
hypersensitivity, and anaphylactic reaction
have been observed, but their occurrence was
very rare (\1/10,000) [25].
Discontinuation of Treatment due to ADRs
For most studies, the rate of premature
discontinuation due to ADRs was under 5%
with the 5% lidocaine medicated plaster
(Table 3) and markedly lower than with
pregabalin (Fig. 2). A higher rate was observed
in a subgroup of a trial with pregabalin as
comparator which included patients with renal
impairment (Table 3).
SAFETY IN SPECIAL PATIENT
POPULATIONS
This section summarizes the 5% lidocaine
medicated plaster use in special patient
populations investigated in clinical studies.
Further clinical particulars are provided in the
summary of product characteristics of the 5%
Fig. 3 Efﬁcacy/tolerability mapping on the basis of one
prospective randomized controlled trial directly comparing
the topical 5% lidocaine medicated plaster and systemic
pregabalin in the treatment of postherpetic neuralgia [17,
19]. Responder rates were deﬁned as a reduction in pain
intensity of at least 2 points or an absolute value of 4 or less
on the 11-point numerical rating scale over the previous
3 days after 4 weeks of treatment
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lidocaine medicated plaster [25]. The safety and
efficacy of 5% lidocaine medicated plaster in
children with PHN below 18 years have not
been studied.
Elderly Patients
As the incidence of PHN increases with age [7–
10], the majority of study patients were elderly
with mean age ranging from 64.9 ± 11.8 to
77.3 ± 7.1 years in the studies reviewed here.
Study results therefore generally apply to elderly
patients.
Pharmacokinetic data showed a general
trend for lidocaine absorption to decrease with
increasing age (additional data from [33], on
file). The amount of lidocaine reaching systemic
circulation thus appears to be even lower in
elderly patients.
Patients with Renal Impairment
Studies specifically investigating efficacy and
safety of the 5% lidocaine medicated plaster in
renally impaired patients have not been carried
out. However, the active comparator study [19]
contained a 5% lidocaine medicated plaster
pick-up arm for patients with renal
impairment (creatinine clearance C30 ml/min
and B60 ml/min at study entry). Nine of the
30 renally impaired patients (30%) experienced
a total of 20 ADRs (Table 3), of which 19
resolved by the end of the trial. Most were
mild or moderate application site reactions. No
serious ADRs were reported. Four patients
(13.3%) discontinued prematurely due to skin-
related ADRs.
The 5% lidocaine medicated plaster can be
used without dose adjustments in patients with
mild or moderate renal impairment, but should
be used with caution in patients with severe
renal dysfunction [25].
Patients with Hepatic Impairment
Studies specifically investigating efficacy and
safety of the 5% lidocaine medicated plaster in
patients with PHN with hepatic dysfunction
have not been carried out. Dose adjustments are
not required in patients with mild or moderate
hepatic impairment, but the 5% lidocaine
medicated plaster should be used with caution
in patients with severe hepatic dysfunction [25].
Cognitive Function
Cognitive integrity in elderly patients with PHN
(mean age 72 ± 8 years) was maintained by
treatment with the lidocaine plaster, whereas
patients on systemic medication (in particular
antidepressants) were significantly impaired in
vigilance, decision making, and semantic
memory [42]. Both treatment groups were
compared to healthy volunteers matched by
age and gender. The authors concluded that the
cognitive impairment associated with pain and
antidepressants might be reversed by topical
pain treatment.
DISCUSSION
The 5% lidocaine medicated plaster is easy to
use and, in contrast to systemic medications,
does not require titration. The treatment was
generally well tolerated by patients suffering
from PHN. Most ADRs were of mild to moderate
intensity, and treatment discontinuation due to
ADRs was rare. The locally acting analgesic has a
very low systemic exposure with maximum
plasma concentrations well below cardiac
therapy levels and potentially toxic
concentrations, and without leading to
lidocaine accumulation [28, 33, 34]. The risk
of systemic ADRs and pharmacokinetic
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interaction with concomitant medications is
therefore low, which allows for a good safety
profile, during both short-term and long-term
treatments. One trial of a direct comparison
with the systemic analgesic pregabalin [19]
points toward comparable efficacy of the two
treatments in PHN pain relief, with a
numerically lower ADR incidence with 5%
lidocaine medicated plaster treatment (Fig. 3).
This is in line with a current review on PHN
treatment in medically complicated patients
highlighting that topical therapies are a
valuable treatment alternative or
complementary treatment to systemic
therapies in this patient group owing to
comorbid disease states and pharmacokinetic
drug interactions [43]. The 5% lidocaine
medicated plaster thus combines proven
efficacy with an excellent safety profile in the
treatment of PHN, thereby improving quality of
life of the patients [17, 19, 24]. Treatment with
5% lidocaine medicated plaster improved
quality of life as measured by EuroQol-5
dimension quality of life index (EQ-5D) health
state to a greater extent than systemic treatment
such as pregabalin [17]. With proven efficacy
and a very limited potential for systemic side
effects and interactions with other medications,
5% lidocaine medicated plaster might improve
patients’ compliance to therapy. A recent
analysis of a cross-sectional survey involving
primary care physicians and pain specialists
suggests higher health-related quality of life and
low pain levels for treatment-compliant
patients [44]. The study found a higher
compliance and a better quality of life in
patients receiving the 5% lidocaine medicated
plaster compared to patients under systemic
treatment. The 5% lidocaine medicated plaster
is a suitable first-line treatment as well as an
alternative for patients unable to tolerate
pregabalin [19]. The 5% lidocaine medicated
plaster is a good alternative in special risk
groups, including elderly patients or patients
with renal impairment. Moreover, owing to its
lack of systemic ADRs, 5% lidocaine medicated
plaster is a suitable treatment for car drivers or
machine operators.
As expected for a topical medication, the
most frequently reported ADRs to the 5%
lidocaine medicated plaster were administration
site reactions. Most application site reactions
were of mild to moderate intensity and often
resolved without further treatment after removal
of the plaster. They were also mainly responsible
for premature treatment discontinuations which
occurred rarely (under 5% of patients).
Headache, nausea, dizziness, dysgeusia, and
somnolence were occasionally reported. They
are known central nervous system reactions
which often occur in the general population
and in particular in multimorbid elderly
patients on concomitant medications.
Dizziness is a frequent ADR with lidocaine
systemically administered as a local anesthetic
[45], and can be encountered when used as an
antiarrhythmic agent [46]. However, lidocaine
plasma concentrations following plaster
application are about 1/10 of the
concentration required for the treatment of
cardiac arrhythmias [47]; a causal relationship
to plaster administration thus seems unlikely.
Single cases of myalgia, hypoglycemia,
unilateral deafness, tinnitus, tachycardia, and
urticaria which were observed under long-term
5% lidocaine medicated plaster treatment were
classified by investigators as possibly drug-
related, according to Sabatowski et al. [21]
probably because they are known ADRs for
systemically administered lidocaine. However,
as discussed before, when administering
lidocaine via the topical-acting medicated
plaster, the low systemic availability of
lidocaine renders a causal relationship unlikely.
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PHN incidence rates markedly increase with
age [7–10] and many elderly patients experience
substantial long-standing debilitating pain,
dysfunction, and poor quality of life [4, 47].
Comorbidities, polypharmacy and thus possible
drug–drug interactions with an increased risk of
ADRs and noncompliance are the challenges of
successful pain treatment in the elderly.
Pharmacological PHN treatment is often
suboptimal and levels of treatment
dissatisfaction are high [48]. The majority of
PHN patients in the reviewed studies were
elderly with a mean age range from
64.9 ± 11.8 to 77.3 ± 7.1 years. The 5%
lidocaine medicated plaster showed a good
safety profile with a low incidence of ADRs
which, combined with efficient pain relief [23],
provides an excellent benefit/risk ratio for the
medication in this elderly patient population.
Another particular concern in the elderly is an
impairment of cognitive abilities by chronic
pain which has been shown in several
publications [49, 50]. Treatment with the 5%
lidocaine medicated plaster maintained
cognitive integrity in elderly patients with
PHN, whereas systemic treatment, in particular
with antidepressants, had a deleterious effect on
several domains of cognition [42]. This finding
adds to the good safety profile of the 5%
lidocaine medicated plaster and renders it a
valuable treatment option.
CONCLUSIONS
The 5% lidocaine medicated plaster
demonstrated good short- and long-term
tolerability with a minimal risk for systemic
ADRs. The 5% lidocaine medicated plaster was
better tolerated than systemic treatment with
pregabalin in one trial. Mild to moderate
application site reactions were the most
frequent ADRs related to topical lidocaine
treatment in a predominantly elderly
population with PHN. Combined with
efficient pain relief, the 5% lidocaine
medicated plaster provides a safe treatment
alternative to systemic medications for PHN
treatment.
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